MET and KRAS gene amplification mediates acquired resistance to MET tyrosine kinase inhibitors

被引：0
|
作者：
Ghiso, E. [1 ]
Cepero, V. [2 ,3 ]
Sierra, J. R. [2 ,3 ]
Corso, S. [1 ]
Casorzo, L. [1 ]
Perera, T. [4 ]
Comoglio, P. M. [1 ]
Giordano, S. [1 ]
机构：
[1] IRCC, Candiolo Turin, Italy
[2] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada
[3] Ontario Canc Inst, Univ Hlth Network, Toronto, ON M4X 1K9, Canada
[4] Ortho Biotech, Oncol Res & Dev, Beerse, Belgium
来源：
EJC SUPPLEMENTS | 2010年 / 8卷 / 07期
关键词：
D O I：
10.1016/S1359-6349(10)72019-X
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：100 / 100
页数：1
相关论文
共 50 条
  • [1] MET and KRAS Gene Amplification Mediates Acquired Resistance to MET Tyrosine Kinase Inhibitors
    Cepero, Virna
    Sierra, J. Rafael
    Corso, Simona
    Ghiso, Elena
    Casorzo, Laura
    Perera, Tim
    Comoglio, Paolo Maria
    Giordano, Silvia
    CANCER RESEARCH, 2010, 70 (19) : 7580 - 7590
  • [2] MET signaling in acquired resistance to irreversible EGF receptor tyrosine kinase inhibitors
    不详
    PHARMACOGENOMICS, 2010, 11 (06) : 745 - 746
  • [3] Acquired Resistance Mechanism for MET Tyrosine Kinase Inhibitor
    Fujino, Toshio
    Mitsudomi, Tetsuya
    JTO CLINICAL AND RESEARCH REPORTS, 2021, 2 (03):
  • [4] MET gene amplification or EGFR mutation activate MET in lung cancers untreated with EGFR tyrosine kinase inhibitors
    Kubo, Takafumi
    Yamamoto, Hiromasa
    Lockwood, William W.
    Valencia, Ilse
    Sob, Junichi
    Peyton, Michael
    Jida, Masaru
    Otani, Hiroki
    Fujii, Tetsuva
    Ouchida, Mamoru
    Takigawa, Nagio
    Kiura, Katsuyuki
    Shimizu, Kenji
    Date, Hiroshi
    Minna, John D.
    Varella-Garcia, Marileila
    Lam, Wan L.
    Gazdar, Adi F.
    Toyooka, Shinichi
    INTERNATIONAL JOURNAL OF CANCER, 2009, 124 (08) : 1778 - 1784
  • [5] MET tyrosine kinase inhibitors
    不详
    NATURE REVIEWS DRUG DISCOVERY, 2008, 7 (06) : 469 - 469
  • [6] Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14-Mutant NSCLC
    Recondo, Gonzalo
    Bahcall, Magda
    Spurr, Liam F.
    Che, Jianwei
    Ricciuti, Biagio
    Leonardi, Giulia C.
    Lo, Ying-Chun
    Li, Yvonne Y.
    Lamberti, Giuseppe
    Nguyen, Tom
    Milan, Marina S. D.
    Venkatraman, Deepti
    Umeton, Renato
    Paweletz, Cloud P.
    Albayrak, Adem
    Cherniack, Andrew D.
    Price, Kristin S.
    Fairclough, Stephen R.
    Nishino, Mizuki
    Sholl, Lynette M.
    Oxnard, Geoffrey R.
    Janne, Pasi A.
    Awad, Mark M.
    CLINICAL CANCER RESEARCH, 2020, 26 (11) : 2615 - 2625
  • [7] MET tyrosine kinase inhibitors in combination with EGFR tyrosine kinase inhibitors in NSCLC patients with EGFR mutations and acquired MET alterations: a systematic review and meta-analysis
    Defeng Hu
    Yixuan Hu
    Shipeng Lei
    Dongdong Wu
    Yubo Wang
    BMC Cancer, 25 (1)
  • [8] A case of EGFR mutant lung adenocarcinoma that acquired resistance to EGFR-tyrosine kinase inhibitors with MET amplification and epithelial-to-mesenchymal transition
    Miyoshi, Seigo
    Kato, Takahide
    Katayama, Hitoshi
    Ito, Ryoji
    Mizuno, Yosuke
    Okura, Takafumi
    Higaki, Jitsuo
    ONCOTARGETS AND THERAPY, 2015, 8 : 783 - 787
  • [9] De novo MET amplification promotes intrinsic resistance to first-generation EGFR tyrosine kinase inhibitors
    Li, Jing-Wen
    Cao, Shu-Hui
    Xu, Jian-Lin
    Zhong, Hua
    CANCER BIOLOGY & THERAPY, 2019, 20 (09) : 1183 - 1186
  • [10] The Efficacy and Safety of Treating Acquired MET Resistance Through Combinations of Parent and MET Tyrosine Kinase Inhibitors in Patients With Metastatic Oncogene-Driven NSCLC
    Patil, Tejas
    Staley, Alyse
    Nie, Yunan
    Sakamoto, Mandy
    Stalker, Margaret
    Jurica, James M.
    Koehler, Kenna
    Cass, Amanda
    Kuykendall, Halle
    Schmitt, Emily
    Filar, Emma
    Reventaite, Evelina
    Davies, Kurt D.
    Nijmeh, Hala
    Haag, Mary
    Yoder, Benjamin A.
    Bunn, Paul A.
    Schenk, Erin L.
    Aisner, Dara L.
    Iams, Wade T.
    Marmarelis, Melina E.
    Camidge, D. Ross
    JTO CLINICAL AND RESEARCH REPORTS, 2024, 5 (02):
12345